Pfizer’s COVID windfall: What’s next for its R&D pipeline?
The COVID-19 pandemic reshaped the global pharmaceutical industry, putting Pfizer at the forefront. Its collaboration with BioNTech to create the first mRNA-based COVID-19 vaccine, Comirnaty, brought in significant revenue and boosted the company’s profile. Now, with billions of dollars in profits, Pfizer must decide how to use this financial boost to drive innovation and expand its research and development (R&D) pipeline. Let’s explore Pfizer’s plans, R&D focus areas, and the challenges it faces.
Keep reading with a 7-day free trial
Subscribe to Winvesta Crisps to keep reading this post and get 7 days of free access to the full post archives.